Previous Article | Next Article 
Journal of Virology, October 2002, p. 10530-10532, Vol. 76, No. 20
0022-538X/02/$04.00+0 DOI: 10.1128/JVI.76.20.10530-10532.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Human Herpesvirus 8 Gene Encodes a Functional Thymidylate Synthase
Gábor Gáspár,1,2 Erik De Clercq,1 and Johan Neyts1*
Rega Institute for Medical Research, Leuven, Belgium,1
Department of Medical Microbiology, University of Szeged, Szeged, Hungary2
Received 15 May 2002/
Accepted 11 July 2002

ABSTRACT
We demonstrate that human herpesvirus 8, obtained from the lymphoma
cell line BC-3 as well as from Kaposi's sarcoma lesions, carries
a gene that encodes a functional thymidylate synthase (TS).
The particular characteristics of this enzyme are studied and
compared to the characteristics of TSs encoded by other organisms.

TEXT
Human herpesvirus 8 (HHV-8) is a gammaherpesvirus that is related
to herpesvirus saimiri (HVS) and rhesus rhadinovirus (RRV) (
17).
HHV-8 replication can be selectively inhibited by several antiherpesvirus
agents, among which cidofovir proved to be the most effective
(
19,
6). The HHV-8 genome encodes several enzymes that are involved
in nucleoside and nucleotide biosynthesis. These include a thymidine
kinase, a ribonucleotide reductase, a dihydrofolate reductase,
and a thymidylate synthase (TS) (
21). The HHV-8-encoded thymidine
kinase (
3,
7,
16) and dihydrofolate reductase (
5) have been
shown to be functional.
TS (5,10-methylenetetrahydrofolate:dUMP C-methyltransferase, EC 2.1.1.45) is an enzyme that catalyzes the reaction of 5,10-methylenetetrahydrofolate and dUMP to dTMP. TS is the only enzyme leading to the de novo synthesis of dTMP, dTDP, and dTTP. The enzyme is a key target for the action of antitumoral drugs (8). HVS and varicella-zoster virus (VZV) have been previously reported to encode a functional TS (9, 22). Human cytomegalovirus, a virus that belongs to the betaherpesvirus family, does not encode a TS but markedly stimulates cellular TS activity in infected human embryonic lung cells (18).
HHV-8 encodes a TS gene (21), and the protein was previously shown to be expressed in the cytoplasm of cells transfected with an expression vector carrying the HHV-8 TS gene, although no proof of functional enzymatic activity was given (5). The gene encoding the TS of HHV-8 is 1,014 bp long, that of HVS is 885 bp long, that of RRV is 1,002 bp long, and that of VZV is 906 bp long. These TSs are markedly shorter than the human counterpart, which is encoded by a gene of 1,533 bp. In Table 1 we present the alignment of the TS of the different herpesviruses with the human TS. This alignment reveals a high degree of amino acid sequence similarity, in particular for the region extending from amino acids 174 to 224 (Table 1). In the region containing the catalytic site, the HHV-8 TS and its human counterpart are 88% identical.
View this table:
[in this window]
[in a new window]
|
TABLE 1. Alignment of part of the TS gene products from various herpesviruses, as well as from E. coli and humans, in the neighborhood of the catalytic sitea
|
We cloned and expressed the TS gene of HHV-8 by using DNA isolated
from the HHV-8-containing BC-3 cell line (ATCC CRL-2277), as
well as from biopsies of Kaposi's sarcoma lesions obtained from
a Belgian case and from a Hungarian case of classic Kaposi's
sarcoma. In addition, the respective TS genes of HVS (C488 strain)
(virus kindly provided by H. Fickenscher, University of Erlangen,
Erlangen, Germany), VZV (OKA strain) (isolated from fibroblasts
infected with the virus), and RRV DNA (DNA kindly provided by
Scott Wong, Oregon Health Sciences University, Portland) were
cloned and expressed. The forward primers used for PCR amplification
of the TS genes contained an
EcoRI site, and the reverse primers
contained a
SalI site. The resulting amplicons were cloned in
pCR4-TOPO TA vector (Invitrogen), and the cloned fragments were
sequenced on both strands by using the Big Dye terminator cycle
DNA sequencing kit (ABI PRISM, Applied Biosystems). The HVS,
VZV, RRV, and BC-3 HHV-8 TS sequences proved to be 100% identical
to the sequences available from the National Center for Biotechnology
Information Blast GenBank. HHV-8 DNA from the Belgian patient
carried an A-G substitution at nucleotide position 21047 and
at nucleotide position 20824. HHV-8 DNA isolated from the Hungarian
patient carried a C-T substitution at position 21012, an A-G
substitution at position 20776, and a T-A substitution at position
20177 (positions refer to the numbering used in GenBank U75698).
The TS genes were subcloned in the bacterial expression vector
pGEX4. This vector allows the production of glutathione
S-transferase
fusion proteins (Amersham Biosciences). The resulting plasmids
were then used to transform competent
Escherichia coli BL21
cells. Cultures were induced with 0.1 mM isopropyl-ß-
D-thiogalactoside
(IPTG) (Sigma) for 6 h at 25°C. Cells were pelleted at 10,000
x g for 10 min at 4°C and resuspended in BugBuster protein
extraction reagent (Novagen). Benzonase nuclease (Novagen) was
added for 20 min at room temperature. Clarified lysates were
pelleted for 20 min at 15,000
x g at 4°C and incubated with
glutathione Sepharose 4B (Amersham Biosciences). The recombinant
enzymes were eluted with glutathione according to the manufacturer's
instructions. The protein concentrations were determined, and
the size of the protein was monitored by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis. TS activity was assessed by means of the
tritium release assay according to a modified version of a method
used earlier (
1). The appropriate amount of enzyme was incubated
with 14.6 Ci of [5-
3H]dUMP (Amersham Pharmacia Biotech)/mmol
in 50 mM Tris-HCl buffer (pH 7.5) containing 5.0 mM formaldehyde,
15 mM ß-mercaptoethanol, 0.1 mM NaF, and (6
R,S)-5,10-methylene-5,6,7,8-tetrahydrofolate
(Schircks Laboratory). According to the particular experimental
conditions, various concentrations of dUMP and 5,10-methylene-5,6,7,8-tetrahydrofolate
were used. The enzymatic reactions were initiated, following
a 2-min preincubation of the reaction mixture at 37°C, by
addition of the enzyme and were then incubated in triplicate
at 37°C for the appropriate time. The enzymatic reaction
was stopped on ice, and 1 ml of active carbon (100 mg/ml in
2% trichloroacetic acid) was added to the tubes. Following a
2-min incubation period on ice, the carbon was pelleted by centrifugation
at 3,000 rpm in a Hereaus Minifuge T for 10 min (4°C). Tritium
release was measured by determining radioactivity in 200-µl
fractions of the supernatant. Enzyme kinetics were calculated
by using Graphpad Prism version 3.02 for Windows (GraphPad Software,
San Diego, Calif.).
HHV-8 TSs, obtained from three sources as described above, i.e., HHV-8 isolated from the BC-3 lymphoma cell line as well as from two different patients with Kaposi's sarcoma, were expressed. Recombinant HHV-8 TSs obtained from these three sources all proved functionally active. Recombinant TSs that were derived from HVS as well as from VZV also exhibited, as expected, functional TS activity. We failed, however, to detect functional TS activity associated with the RRV TS even though alternative cloning strategies were used and a protein of the correct size was expressed. The question remains whether the RRV TS is indeed functionally active or whether the particular RRV strain that was used here encodes a defective TS.
We next studied and compared the particular kinetics of the TS of HHV-8, HVS, and VZV. Km values, with dUMP and methylenetetrahydrofolate (CH2H4-folate) as a substrate, for the TSs encoded by HHV-8 (DNA obtained from the Kaposi's sarcoma lesion of a Belgian patient), HVS, and VZV are summarized in Table 2. Km values of E. coli TS (enzyme kindly provided by Paola Costi, University of Modena, Modena, Italy) and of human TS (data obtained from the literature) are also listed. Km values for both substrates (dUMP and CH2H4-folate) were very comparable to those of the three herpesvirus enzymes and were in the same range as the Km values reported for human TS (14).
We then investigated the inhibitory effects of three well-known
TS inhibitors, i.e., 5-fluoro-2'-deoxyuridine-5'-monophosphate
(FdUMP) (Sigma), 5-iodo-2'-deoxyuridine-5'-mono-phosphate (IdUMP)
(Sigma), and 5-(2-bromovinyl)-2'-deoxyuridine-monophosphate
(BVdUMP) (kindly provided by P. Herdewijn, Rega Institute, Leuven,
Belgium), and of dTMP (Sigma) (which is a product inhibitor
of TS) on the three viral enzymes. For all three dUMP analogues
studied, the type of inhibition was competitive with respect
to dUMP. The TS encoded by HHV-8, HVS, and VZV proved as susceptible
to the compounds as the human, murine, and lactobacillus thymidylate
synthases (Table
3). This makes it unlikely that HHV-8 is a
specific target for antiviral or antitumoral therapy against
HHV-8 or tumors associated with HHV-8.
View this table:
[in this window]
[in a new window]
|
TABLE 3. Comparison of rates of inhibition of herpesvirus, human, murine, and Lactobacillus casei TSs by 5-substituted dUMP analogues and dTMP
|
Evidence that cellular TSs from diverse species influence the
regulation of p53 expression by decreasing the translational
efficiency of p53 mRNA has been provided (
11). It is also assumed
that inhibition of p53 by the HHV-8 latency-associated nuclear
antigen may be involved in HHV-8-induced oncogenesis by suppression
of cell death (
12). It would be tempting to speculate that HHV-8
TS plays a role in HHV-8-induced oncogenesis. In such a case,
the viral TS could be one of the many factors, including the
viral G protein-coupled receptor, the viral interferon regulatory
factor, viral D-type cyclin, viral interleukin-6, viral bcl-2,
viral FLICE-inhibitory protein, latency-associated nuclear antigen,
K1, and latency-associated membrane protein, that are associated
with virus-induced oncogenesis (
10).

ACKNOWLEDGMENTS
Gábor Gáspár is a recipient of a Soros-KU
Leuven grant. This work was supported by a grant from Geconcentreerde
Onderzoeksacties (GOA 00/12) and from the Belgian Federation
Against Cancer. Johan Neyts is a Fellow of the Flemish "Fonds
voor Wetenschappelijk Onderzoek (FWO)."

FOOTNOTES
* Corresponding author. Mailing address: Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. Phone: 32-16-337341. Fax: 32-16-337340. E-mail:
Johan.Neyts{at}rega.kuleuven.ac.be.


REFERENCES
1 - Balzarini, J., E. De Clercq, M. P. Mertes, D. Shugar, and P. F. Torrence. 1982. 5-Substituted 2'-deoxyuridines: correlation between inhibition of tumor cell growth and inhibition of thymidine kinase and thymidylate synthetase. Biochem. Pharmacol. 31:3673-3682.[CrossRef][Medline]
2 - Barr, P. J., N. J. Oppenheimer, and D. V. Santi. 1983. Thymidylate synthetase-catalyzed conversions of E-5-(2-bromovinyl)-2'-deoxyuridylate. J. Biol. Chem. 258:13627-13631.[Abstract/Free Full Text]
3 - Cannon, J. S., F. Hamzeh, S. Moore, J. Nicholas, and R. F. Ambinder. 1999. Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J. Virol. 73:4786-4793.[Abstract/Free Full Text]
4 - Carreras, C. W., S. C. Climie, and D. V. Santi. 1992. Thymidylate synthase with a C-terminal deletion catalyzes partial reactions but is unable to catalyze thymidylate formation. Biochemistry 31:6038-6044.[CrossRef][Medline]
5 - Cinquina, C. C., E. Grogan, R. Sun, S. F. Lin, G. P. Beardsley, and G. Miller. 2000. Dihydrofolate reductase from Kaposi's sarcoma-associated herpesvirus. Virology 268:201-217.[CrossRef][Medline]
6 - De Clercq, E., L. Naesens, L. De Bolle, D. Schols, Y. Zhang, and J. Neyts. 2001. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev. Med. Virol. 11:381-395.[CrossRef][Medline]
7 - Gustafson, E. A., R. F. Schinazi, and J. D. Fingeroth. 2000. Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir. J. Virol. 74:684-692.[Abstract/Free Full Text]
8 - Hatse, S., E. De Clercq, and J. Balzarini. 1999. Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. Biochem. Pharmacol. 58:539-555.[CrossRef][Medline]
9 - Honess, R. W., W. Bodemer, K. R. Cameron, H. H. Niller, B. Fleckenstein, and R. E. Randall. 1986. The A+T-rich genome of Herpesvirus saimiri contains a highly conserved gene for thymidylate synthase. Proc. Natl. Acad. Sci. USA 83:3604-3608.[Abstract/Free Full Text]
10 - Jenner, R. G., and C. Boshoff. 2002. The molecular pathology of Kaposi's sarcoma-associated herpesvirus. Biochim. Biophys. Acta 1602:1-22.[Medline]
11 - Ju, J., J. Pedersen-Lane, F. Maley, and E. Chu. 1999. Regulation of p53 expression by thymidylate synthase. Proc. Natl. Acad. Sci. USA 96:3769-3774.[Abstract/Free Full Text]
12 - Katano, H., Y. Sato, and T. Sata. 2001. Expression of p53 and human herpesvirus-8 (HHV-8)-encoded latency-associated nuclear antigen with inhibition of apoptosis in HHV-8-associated malignancies. Cancer 92:3076-3084.[CrossRef][Medline]
13 - Lackey, D. B., M. P. Groziak, M. Sergeeva, M. Beryt, C. Boyer, R. M. Stroud, P. Sayre, J. W. Park, P. Johnston, D. Slamon, H. M. Shepard, and M. Pegram. 2001. Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase. Biochem. Pharmacol. 61:179-189.[CrossRef][Medline]
14 - Landis, D. M., and L. A. Loeb. 1998. Random sequence mutagenesis and resistance to 5-fluorouridine in human thymidylate synthases. J. Biol. Chem. 273:25809-25817.[Abstract/Free Full Text]
15 - Landis, D. M., C. C. Heindel, and L. A. Loeb. 2001. Creation and characterization of 5-fluorodeoxyuridine-resistant Arg50 loop mutants of human thymidylate synthase. Cancer Res. 61:666-672.[Abstract/Free Full Text]
16 - Lock, M. J., N. Thorley, J. Teo, and V. C. Emery. 2002. Azidodeoxythymidine and didehydrodeoxythymidine as inhibitors and substrates of the human herpesvirus 8 thymidine kinase. J. Antimicrob. Chemother. 49:359-366.[Abstract/Free Full Text]
17 - Moore, P. S., and Y. Chang. 2001. Molecular virology of Kaposi's sarcoma-associated herpesvirus. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356:499-516.[Abstract/Free Full Text]
18 - Neyts, J., J. Verbiest, A. Meerbach, and E. De Clercq. 1995. Human Cytomegalovirus stimulates thymidylate synthase in human embryonic lung cells: a possible target for anti-HCMV therapy? Nucleosides Nucleotides 14:1153-1156.[CrossRef]
19 - Neyts, J., and E. De Clercq. 1997. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob. Agents Chemother. 41:2754-2756.[Abstract]
20 - Rode, W., T. Kulikowski, B. Kedzierska, M. Jastreboff, and D. Shugar. 1984. Inhibition of mammalian tumour thymidylate synthetase by 5-alkylated 2'-deoxyuridine 5'-phosphates. Biochem. Pharmacol. 33:2699-2705.[CrossRef][Medline]
21 - Russo, J. J., R. A. Bohenzky, M. C. Chien, J. Chen, M. Yan, D. Maddalena, J. P. Parry, D. Peruzzi, I. S. Edelman, Y. Chang, and P. S. Moore. 1996. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc. Natl. Acad. Sci. USA 10:14862-14867.
22 - Thompson, R., R. W. Honess, L. Taylor, J. Morran, and A. J. Davison. 1987. Varicella-zoster virus specifies a thymidylate synthetase. J. Gen. Virol. 68:1449-1455.[Abstract/Free Full Text]
23 - Wataya, Y., D. V. Santi, and C. Hansch. 1977. Inhibition of Lactobacillus casei thymidylate synthetase by 5-substituted 2'-deoxyuridylates. Preliminary quantitative structure-activity relationship. J. Med. Chem. 20:1469-1473.[CrossRef][Medline]
Journal of Virology, October 2002, p. 10530-10532, Vol. 76, No. 20
0022-538X/02/$04.00+0 DOI: 10.1128/JVI.76.20.10530-10532.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Zhu, W., Burnette, A., Dorjsuren, D., Roberts, P. E., Huleihel, M., Shoemaker, R. H., Marquez, V. E., Agbaria, R., Sei, S.
(2005). Potent Antiviral Activity of North-Methanocarbathymidine against Kaposi's Sarcoma-Associated Herpesvirus. Antimicrob. Agents Chemother.
49: 4965-4973
[Abstract]
[Full Text]